These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2008-008794-55||A randomised phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma||2014-02-15||due-trials|
|Reported results Terminated||2012-000542-35||Phase II multicentre study assessing the efficacy of Cabazitaxel in Patients with HER2-negative metastatic breast cancer and having unresectable brain metastases.||2018-07-25||due-trials|
|Ongoing||2012-004895-21||Phase II randomised placebo controlled NEOadjuvant chemotherapy study of Nintedanib with Gemcitabine and Cisplatin in locally advanced muscle invasive BLADder cancEr||not-yet-due|
|Ongoing||2014-002382-30||Phase II study of neoadjuvant cisplatin and gemcitabine chemotherapy versus upfront surgery in patients with resectable proximal biliary tract cancer:||not-yet-due|
|Ongoing||2014-004653-14||A Phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with Gemcitabine in patient with metastatic pancreatic carcinoma. (ACELARATE)||not-yet-due|
|Ongoing||2016-004215-13||Randomised Phase II Trial of Cediranib and Olaparib Maintenance in Advanced/Recurrent Cervical Cancer (COMICE)||not-yet-due|
|Ongoing||2017-005015-13||NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer||not-yet-due|
|Ongoing||2018-000004-42||TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE/TAE for patients with intermediate stage HCC||not-yet-due|
|Ongoing||2019-000842-36||A Polatuzumab Vedotin Containing Chemo-Immunotherapeutic Regimen in Patients with Diffuse Large B-Cell Lymphoma Unsuitable for Full Dose R-CHOP Therapy||not-yet-due|